Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
about
The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant RecipientsThe perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejectionRecent advances in renal transplantation: antibody-mediated rejection takes center stageThe Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation.Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience.Many de novo donor-specific antibodies recognize β2 -microglobulin-free, but not intact HLA heterodimers.Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection.Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management.Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant.mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now?Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney transplant recipients: A multicenter Midwest Pediatric Nephrology Consortium study.Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants.Early subclinical inflammation correlates with outcomes in positive crossmatch kidney allografts.Therapy Modalities for Antibody Mediated Rejection in Renal Transplant Patients.Successful treatment of severe acute antibody-mediated rejection of renal allografts with bortezomib--a report of two pediatric cases.Rituximab use in late antibody-mediated rejectionAcute Rejection in Renal Transplant Patients of a Hospital in Bogota, ColombiaBortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.Complement C5 Inhibition Reduces T Cell-Mediated Allograft Vasculopathy Caused by Both Alloantibody and Ischemia Reperfusion Injury in Humanized Mice.Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation.A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.Triptolide inhibits donor-specific antibody production and attenuates mixed antibody-mediated renal allograft injury.The lack of Lazarus effect with proteasome inhibition.Acute rejection.Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study.Molecular Assessment of Microcirculation Injury in Formalin-Fixed Human Cardiac Allograft Biopsies With Antibody-Mediated Rejection.Antibody-mediated rejection: New approaches in prevention and management.[Rehabilitation after kidney transplantation: Old problems and new structures].
P2860
Q26774993-DA384FE5-62AB-44B3-8440-AE96C6C0D280Q26862195-8CCF484F-43B7-4A14-A4BF-2DAE71CC0EDBQ35659332-4F9439AB-FEB7-43D0-85D4-AFB3452025D4Q36240178-4B3510D6-CF6E-42E3-A58E-0231FDAA9596Q37241071-C153D4EA-4C14-4E89-AFED-4526F77A3AD2Q37352506-E70C4B4A-6EEE-40C4-A774-D2F55C4FC996Q38282840-E464797A-FF94-4AAD-974F-C20752AF2F40Q38392458-50AAFE1A-C462-4950-B116-DC39C225FE7AQ38731333-400FF767-11F4-462C-A3D5-E4402F5B03A2Q38818479-E4FFAE0D-6E84-48C5-A852-29AFA4C76FFEQ39018530-6B16FA29-3C35-4BF2-A75B-31610B014246Q39350215-15C80AAC-58CE-4699-B675-C1E4E68A2B6CQ39736122-829AADB7-2FD6-4B94-AB38-814ACC6DBD2CQ40745610-8BF7B810-5B18-4B35-A5E0-28ABA287E54AQ40958100-F72F63E8-65AB-40B1-AE30-8FCE80EFE55AQ41041729-F04B3266-BD63-4F70-B85B-240968E456A7Q41358191-3CCDF43E-87A4-4226-B119-EB0F078CDCC3Q41495990-7A975FC8-AF03-4BD8-B4EE-98C795A304EEQ41631576-FA2F48AD-F28B-49C7-8E61-E59587F34D70Q42372206-918D2F0C-A583-49D2-AEAD-336B1B2AA01AQ47292306-ED7BE979-8FB9-40EC-BAFF-32835AF2B30CQ47311433-A81F8882-5216-47EA-A21A-433E327FAE59Q47443910-40F0B24C-3180-460E-BA0C-781D2AFE0FFDQ47744928-EDE032CC-9A54-44FF-B0CF-73662C78E1B0Q47987136-74A239B7-6D69-4E29-8F71-8F110B79B2F5Q48165787-6668EE98-8DBA-47EF-8F21-47CC56AF4CE3Q52401610-6A646396-B33A-4477-A8C3-7E1A15BF1A68Q52859573-B21B34FD-58FC-4279-94C1-990ECD3E78A9
P2860
Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Late antibody-mediated rejecti ...... ventional and novel therapies.
@en
Late antibody-mediated rejecti ...... ventional and novel therapies.
@nl
type
label
Late antibody-mediated rejecti ...... ventional and novel therapies.
@en
Late antibody-mediated rejecti ...... ventional and novel therapies.
@nl
prefLabel
Late antibody-mediated rejecti ...... ventional and novel therapies.
@en
Late antibody-mediated rejecti ...... ventional and novel therapies.
@nl
P2093
P1433
P1476
Late antibody-mediated rejecti ...... nventional and novel therapies
@en
P2093
Andrea A Zachary
Bassam G Abu Jawdeh
Bhavna Bhasin
Brandon Trollinger
Edward Kraus
Hamid Rabb
Lois J Arend
Lorraine C Racusen
Robert A Montgomery
P304
P356
10.1097/01.TP.0000442503.85766.91
P577
2014-06-01T00:00:00Z